Domain licenses Parkinson's drug candidates to Merck Serono spinoff

01/24/2013 | Genetic Engineering & Biotechnology News

Merck Serono spinoff Prexton Therapeutics was given an exclusive option by Domain Therapeutics to advance through clinical development stage its metabotropic glutamate receptor 4-positive allosteric modulator drug candidates against Parkinson's disease. The chemical series emerged from joint work by Domain and Merck Serono.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC